Drug intelligence / Profile preview

AFT-SP2

Development stage: Preclinical
Lead developer: AFT Pharmaceuticals
Administration: Injectable

Overview

AFT-SP2 is a preclinical-stage, thermostable reformulation of an undisclosed sterile injectable drug, developed through a partnership between Stablepharma and AFT Pharmaceuticals. The product utilizes Stablepharma's proprietary stabilization technology (StablevaX) to create a fridge-free version of an existing therapeutic, aimed at improving logistics and access in the anti-infective and oncology sectors. As of 2024, the specific active ingredient and mechanism of action have not been publicly disclosed, and the program is in the early research phase with no immediate clinical trials scheduled.

Beyond the preview

Go deeper on AFT-SP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFT-SP2.

Explore the full profile